TP53 and neoplasm: In a similar context, Chen et al. [10] demonstrated that Cyclin D1 inhibition, combined with activation of p53 and p21, reduced tumor cell proliferation, reinforcing the concept of Cyclin D1 as a possible therapeutic target in this subtype.